within Pharmacolibrary.Drugs.N_NervousSystem.N05C_HypnoticsAndSedatives.N05CF02_Zolpidem;

model Zolpidem
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.7,
    Cl = 5.444444444444445e-06,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.00054,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.02,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Zolpidem</td></tr><tr><td>ATC code:</td><td>N05CF02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.54</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.28</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Zolpidem is a non-benzodiazepine hypnotic agent of the imidazopyridine class primarily used for the short-term treatment of insomnia. It works by enhancing the activity of gamma-aminobutyric acid (GABA) via selective agonism at the benzodiazepine-1 (omega-1) receptor subtype. Zolpidem is approved and widely used today for sleep disorders.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported in healthy adult volunteers (both sexes), typically aged 18-45 years, under fasting conditions after single oral dose.</p><h4>References</h4><ol><li><p>Monti, JM, et al., &amp; Pandi-Perumal, SR (2017). Zolpidem&#x27;s use for insomnia. <i>Asian journal of psychiatry</i> 25 79–90. DOI:<a href=\"https://doi.org/10.1016/j.ajp.2016.10.006\">10.1016/j.ajp.2016.10.006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28262178/\">https://pubmed.ncbi.nlm.nih.gov/28262178</a></p></li><li><p>Guo, T, et al., &amp; Yang, L (2014). Comparative pharmacokinetics of zolpidem tartrate in five ethnic populations of China. <i>Acta pharmaceutica Sinica. B</i> 4(2) 146–150. DOI:<a href=\"https://doi.org/10.1016/j.apsb.2014.02.001\">10.1016/j.apsb.2014.02.001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26579377/\">https://pubmed.ncbi.nlm.nih.gov/26579377</a></p></li><li><p>Shen, M, et al., &amp; Xiang, P (2013). CYP3A4 and CYP2C19 genetic polymorphisms and zolpidem metabolism in the Chinese Han population: a pilot study. <i>Forensic science international</i> 227(1-3) 77–81. DOI:<a href=\"https://doi.org/10.1016/j.forsciint.2012.08.035\">10.1016/j.forsciint.2012.08.035</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22964165/\">https://pubmed.ncbi.nlm.nih.gov/22964165</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05CF02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Zolpidem;
